Home › Alexion's Soliris (eculizumab) Receives Orphan Drug Designation For The Treatment Of Neuromyelitis Optica (NMO)
 

Keywords :   


Alexion's Soliris (eculizumab) Receives Orphan Drug Designation For The Treatment Of Neuromyelitis Optica (NMO)

2013-06-27 18:50:00| drugdiscoveryonline News Articles

Alexion Pharmaceuticals, Inc. recently announced that Soliris (eculizumab), the company’s first-in-class terminal complement inhibitor, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of neuromyelitis optica (NMO), a life-threatening, ultra-rare neurological disorder

Tags: treatment drug receives designation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Atlantic Tropical Weather Outlook
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Public Advisory Number 3A
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Eastern North Pacific Tropical Weather Outlook
06.10Hurricane Leslie Graphics
06.10Hurricane Kirk Graphics
06.10Hurricane Leslie Forecast Discussion Number 15
More »